Data protection Impressum

Medtech

Innovaud has awarded the Scale-Up Vaud 2025 label to 42 high-growth companies, including nine new entrants, reinforcing the region’s dynamic innovation ecosystem.

Business environment

42 Vaud-based companies awarded Scale-Up Vaud 2025 label

3 March 2025

Top Stories Western Switzerland

Top Stories from Western Switzerland (February 2025)

25 February 2025

Biotech company CELLnTEC is playing a key role in the NEOLIVER project, a European-Swiss initiative developing the world’s first autologous bioprinted liver for clinical use. The project, co-funded by the EU and the Swiss government, aims to address the global organ donor shortage through innovative bioprinting technologies.

Bern-based CELLnTEC joins NEOLIVER project to develop bioprinted liver constructs

10 February 2025

The Foundation for Innovation and Technology has awarded Tech Grants to five promising projects from CHUV, EPFL, and HEIG-VD. The grants will support innovations in medical technology, robotics, and sustainable agriculture.

FIT awards Tech Grants to five cutting-edge projects from CHUV, EPFL and HEIG-VD

5 February 2025

Swiss start-ups raised CHF 2.4 billion in venture capital in 2024, marking an 8.5% decline from the previous year. The number of financing rounds also fell for the first time, reflecting a challenging investment climate. Despite these setbacks, biotech and cleantech sectors saw strong growth, and investor sentiment remains optimistic for 2025.

Swiss start-ups secure CHF 2.4 billion in 2024 amid shifting investment trends

4 February 2025

The Human Lean Diagnostics (HLD) innovation cluster in Neuchâtel is preparing to welcome its first tenants in June 2025. Developed in collaboration with Microcity, the cluster is dedicated to accelerating medical diagnostics innovation by providing state-of-the-art infrastructure, fostering collaboration between industry and academia, and strengthening Switzerland’s position in health technology.

Neuchâtel’s Human Lean Diagnostics cluster is set to welcome its first tenants

29 January 2025

TheraMe!, a Lausanne-based medtech, is transforming cancer treatment by partnering with CSEM to develop an automated, microfluidic-based instrument. This breakthrough technology enables personalized drug screening on live tumor samples, providing cancer patients with tailored therapy recommendations before treatment begins.

CSEM and TheraMe! transform cancer therapy with personalized drug screening technology

28 January 2025

EPFL Innovation Park biotech company AB2 Bio has signed an option and licensing agreement with Japan-based Nippon Shinyaku to advance Tadekinig alfa, a novel treatment for Primary Monogenic IL-18 driven Hyperinflammatory Syndrome. The deal includes up to USD 36 million in early payments and milestone-based funding of up to USD 650 million.

AB2 Bio secures USD 650 million partnership with Nippon Shinyaku for rare disease therapy

27 January 2025

EBAMed has secured an additional EUR 1.6 million in Series A funding, bringing the total raised to EUR 16 million. This new investment, contributed by CDP Venture Capital and the European Union, supports the development of EBAMed’s groundbreaking CardioKit system for non-invasive treatment of heart arrhythmias using Proton Therapy.

Geneva medtech EBAMed completes financing round with EUR 16 million

27 January 2025

Geneva-based BrainScape Medical, a newly incorporated company specializing in neuromonitoring and neurostimulation technologies, has announced several milestones, including new leadership, FDA Breakthrough Device Designation, and promising results from its first human trials.

BrainScape Medical makes strides in long-term brain monitoring

21 January 2025

1 2 3 4 5 6 7 … 17